Disclosures for "Correlations between Clinical and Brain Volume Effects of Oral Valiltramiprosate in APOE4/4 Homozygotes with MCI: Pre-specified Analyses of the Phase-3 APOLLOE4 78-Week Trial in APOE4/4 Homozygotes with Early Alzheimer’s Disease (AD)"
-
Dr. Sabbagh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eisai. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genetech=Roche. Dr. Sabbagh has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novo Nordisk. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Dr. Sabbagh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Synaptogenix. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Signant Health. Dr. Sabbagh has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Anavex. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cognito Therapeutics. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GSK. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Sabbagh has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for CervoMed. Dr. Sabbagh has stock in Neurotau. Dr. Sabbagh has stock in Seq Biomarque. Dr. Sabbagh has stock in uMethod Health. Dr. Sabbagh has stock in Athira. Dr. Sabbagh has stock in Lighthouse Pharmaceuticals. Dr. Sabbagh has stock in Alzheon. The institution of Dr. Sabbagh has received research support from NIH. The institution of Dr. Sabbagh has received research support from ADDF.
-
Dr. Abushakra has received personal compensation for serving as an employee of Alzheon Inc.. Dr. Abushakra has stock in Alzheon Inc.. The institution of Dr. Abushakra has received research support from NIH. Dr. Abushakra has received intellectual property interests from a discovery or technology relating to health care.
-
Prof. Tosun has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alzheon. The institution of Prof. Tosun has received research support from NIH.
-
Dr. Watson has nothing to disclose.
-
Dr. Power has received personal compensation for serving as an employee of Alzheon. Dr. Power has stock in Pfizer. Dr. Power has stock in Alzheon.
-
Dr. Liang has nothing to disclose.
-
Author has nothing to disclose
-
Author has nothing to disclose
-
Dr. bennys has nothing to disclose.
-
Author has nothing to disclose
-
Dr. Hey has received personal compensation for serving as an employee of Alzheon. Dr. Hey has stock in Alzheon. Dr. Hey has stock in Alzheon. Dr. Hey has received intellectual property interests from a discovery or technology relating to health care.
-
Ms. Flint has received personal compensation for serving as an employee of Alzheon. Ms. Flint has stock in Alzheon.
-
Dr. Kesslak has received personal compensation for serving as an employee of Alzheon.
-
Mr. Bracoud has nothing to disclose.
-
Dr. Bray has received personal compensation for serving as an employee of Amgen Ltd. Dr. Bray has stock in Amgen Ltd.
-
Dr. Tolar has received personal compensation for serving as an employee of Alzheon. Dr. Tolar has received intellectual property interests from a discovery or technology relating to health care.